Compounds > e-ebu-dm
Page last updated: 2024-09-27

e-ebu-dm

Cross-References

ID SourceID
PubMed CID453151
CHEMBL ID310976
SCHEMBL ID2107018
MeSH IDM0290600

Synonyms (15)

Synonym
CHEMBL310976 ,
6-(3,5-dimethylbenzyl)-1-ethoxymethyl-5-ethyl-1,2,3,4-tetrahydro-2,4-pyrimidine dione
6-(3,5-dimethyl-benzyl)-1-ethoxymethyl-5-ethyl-1h-pyrimidine-2,4-dione
bdbm50032235
6-[(3,5-dimethylphenyl)methyl]-1-(ethoxymethyl)-5-ethyl-pyrimidine-2,4-dione
136160-30-0
5-ethyl-1-ethoxymethyl-6-(3,5-dimethylbenzyl)uracil
e-ebu-dm
2,4(1h,3h)-pyrimidinedione, 6-[(3,5-dimethylphenyl)methyl]-1-(ethoxymethyl)-5-ethyl-
6-[(3,5-dimethylphenyl)methyl]-1-(ethoxymethyl)-5-ethylpyrimidine-2,4-dione
1-ethoxymethyl-5-ethyl-6-(3,5-dimethylbenzyl)uracil
2,4(1h,3h)-pyrimidinedione, 6-((3,5-dimethylphenyl)methyl)-1-(ethoxymethyl)-5-ethyl-
SCHEMBL2107018
DTXSID00159709
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-ethylpyrimidine-2,4(1h,3h)-dione

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.00160.00040.61539.7000AID200009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID105530Effective dose of compound required to inhibit 50% of HIV-1 antigen production in MT-4 cultures.1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID104945Cytotoxic dose required to reduce the proliferation of normal uninfected MT-4 cells1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID46051Tested for inhibitory concentration on HIV-I Lai wild type in CEM-SS cell line2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
AID104938Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID235484Selectivity index is the ratio of CC50 to IC502000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
AID235474Selectivity index is the ratio between CD50 and ED501996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID45180Tested for cytotoxic concentration on HIV-I Lai wild type in CEM-SS cell line2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
AID105513Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID200009Inhibitory concentration against HIV-1 reverse transcriptase1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil[no description available]medium30pyrimidone
zidovudine[no description available]medium30azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine[no description available]medium10aryl sulfide;
primary alcohol;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
emivirine[no description available]medium30pyrimidoneantiviral drug;
HIV-1 reverse transcriptase inhibitor
1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil[no description available]medium10aryl sulfide;
pyrimidone
5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil[no description available]medium10
5-ethyl-1-benzyloxymethyl-6-(phenylthio)uracil[no description available]medium10
nevirapine[no description available]medium20cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
3-dimethylamino-4-(3,5-dimethylbenzyl)-5-ethyl-6-methylpyridin-2(1h)-one[no description available]medium10
r-82913[no description available]medium20
uracil[no description available]medium10pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection0low10
HIV Infections0low10
HTLV-III Infections0low10
HTLV-III-LAV Infections0low10
T-Lymphotropic Virus Type III Infections, Human0low10